期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PI3K/Akt通路与表皮生长因子受体酪氨酸激酶抑制剂产生耐药性的关系研究进展 被引量：10

PI3K/Akt signaling pathway and resistance to epithelial growth factor receptor tyrosine kinase inhibitors
下载PDF
导出
摘要 表皮生长因子受体酪氨酸激酶抑制剂(epithelial growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs)是近年来备受关注的一类肿瘤靶向治疗药物,具有很强的作用效果,能够明显提高某些癌症患者的生存质量,但最终几乎所有患者都会产生耐药性导致肿瘤进展。PI3K/Akt信号通路能够调节肿瘤细胞的增殖和存活,与肿瘤的侵袭转移行为密切相关。最近研究发现PI3K/Akt信号通路在EGFR-TKIs产生耐药性中也发挥重要作用。该文对该通路与EGFR-TKIs产生耐药性的关系的研究进展作一综述。 Epithelial growth factor receptor tyrosine kinase inhibi- tor （EGFR-TKIs） is a kind of drugs for cancer targeted therapy which has received wide attention rec, ently. It＇ s been proved that EGFR-TKls has an excellent effect on cancers and can markedly improve life quality of some patients. However, almost all of the patients who have taken the medicine would develop resistance to these drugs, which leads to cancer progress. PI3K/Akt signaling pathway can regulate the proliferation and survival of tumor cells,moreover, it is closely involved in tumor invasion and metastasis. And lately it has been found that PI3K/Akt signaling pathway plays an important role in developing resistance to EGFR-TKIs. So this paper reviews the relationship between PI3K/Akt signa- ling pathway and the mechanisms of resistance to EGFR-TKIs.
作者 刘姣 李明春
机构地区 解放军第
出处 《中国药理学通报》 CAS CSCD 北大核心 2013年第12期1648-1650,共3页 Chinese Pharmacological Bulletin
关键词 P13K AKT信号通路 表皮生长因子受体酪氨酸激酶 抑制剂 分子靶向药物 耐药性 靶向治疗 肿瘤 PI3K/Akt signaling pathway epitbelial growth factor receptor tyrosine kinase inhibitor molecular targeted drug drug resistance targeted therapy cancer
分类号 R-05 [医药卫生] R329.25 [医药卫生—人体解剖和组织胚胎学]
  • 相关文献

参考文献2

二级参考文献46

  • 1Xiong X H,Fu L L,Wang L,et al.Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo[J].Invest New Drugs,2009,27:1-11.
  • 2Zou Z Q,Zhang X H,Wang F,et al.A novel dual PI3K·/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells[J].Inter J Mol Med,2009,24:97-101.
  • 3Ueda Y,Igishi T,Hashimoto K,et al.Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells:Implication of c-Src and its inhibitor[J].International J Oncol,2009,342:689-96.
  • 4Cho Y,Park M J,Park M,et al.Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells[J].Respirology,2009,14(6):850-8.
  • 5Magesh V,Lee J C,Ahn K S,et al.Ocimum sanctum induces apoptosis in A549 lung cancer cells and suppresses the in vivo growth of lewis lung carcinoma cells[J].Phytother Res,2009,23(10):1385-91.
  • 6Bao R,Lai C J,Wang D G,et al.Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer[J].Mol Cancer Ther,2009,8(12):3296-306.
  • 7Matsuzaki H,Ichino A,Hayashi T,et al.Regulation of intracellular localizationand transcriptional activity of FOXO4 by proteinkinaseB through phosphorylation at the motif sites conserved among the FOXO family[J].J Biochem,2005,138:485-91.
  • 8Maekawa T,Maniwa Y,Doi T,et al.Expression and localization of FOXO1 in non-small cell lung cancer[J].Oncol Rep,2009,22:57-64.
  • 9Luo J L,Kamata H,Karin M.IKK/NF-κB signaling:balancing life and death-a new approach to cancer therapy[J].Clin Invest,2005,115:2625-32.
  • 10Lee D F,Kuo H P,Chen C T,et al.IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway[J].Cell,2007,130:440-55.

共引文献23

同被引文献129

  • 1潘振奎,张力,张星,王欣,李宁,徐菲,常建华,管忠震.中国非小细胞肺癌患者表皮生长因子受体突变的研究[J].癌症,2005,24(8):919-923. 被引量：44
  • 2吴健虹,谢秋玲,陈小佳,洪岸.表皮生长因子受体EGFR及其信号传导[J].生命科学,2006,18(2):116-122. 被引量：40
  • 3王超群,郭敏,易敏之,卢建中.山楂化学成分及高效液相色谱分析方法研究进展[J].中国中医药信息杂志,2006,13(11):93-95. 被引量：13
  • 4Singh J, Petter R C, Baillie T A, Whitty A. The resurgence of co- valent drugs[J]. Nat Rev Drug Discov, 2011, 10(4) :307 - 17.
  • 5Singh J, Petter R C, Kluge A F. Targeted covalent drugs of the ki- nase family[J]. Curr Opin Chem Biol, 2010, 14(4) :475 -80.
  • 6Doebele R C, Oton A B, Peled N, et al. New strategies to over- come limitations of reversible EGFR tyrosine kinase inhibitor thera- py in non-small cell lung cancer[ J]. Lung Cancer, 2010, 69( 1 ) : 1 -12.
  • 7Leproult E, Barluenga S, Moras D, et al. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: applica- tion to the design of selective covalent inhibitors [ J ]. J Med Chem, 2011, 54(5) :1347 -55.
  • 8Carmi C, Lodola A, Rivara S, et al. Epidermal growth factor re- ceptor irreversible inhibitors: chemical exploration of the eysteine- trap portion[J]. Mini Rev Med Chem, 2011, 11(12) :1019 -30.
  • 9Lou Y, Owens T D, Kuglstatter A, et al. Bruton' s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preelini- cal and clinical evaluation for inflammatory diseases and B cell ma- lignaneies[J]. J Med Chem, 2012,55(10) :4539 -50.
  • 10Zhou W, Hur W, McDermott U, et al. A structureguided approach to creating covalent FGFR inhibitors [ J ]. Chem Biol, 2010, 17 (3) :285 -95.

引证文献10

二级引证文献48

中国药理学通报
2013年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部